The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain

Magnetic Resonance Imaging

Volumn 26, Issue 5, 2008, Pages 608-617

  Hanaoka, Kenjiro ^a   Lubag, Angelo Josue M ^b   Castillo Muzquiz, Aminta ^c   Kodadek, Thomas ^a   Sherry, A Dean ^b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Anti FLAG antibody; Gadolinium; Microdomain; Targeted MRI contrast agents

Indexed keywords

AGAROSE; ANTIBODY; CONTRAST MEDIUM; GADOLINIUM; PROTEIN; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; DOTA NHS; DOTA-NHS; FLAG PEPTIDE; GADOLINIUM 1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETATE; GADOTERIC ACID; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND; PEPTIDE; SINGLE HETEROCYCLIC RINGS; SUCCINIMIDE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; FLUORESCENCE ANALYSIS; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN;

CONTRAST MEDIA; HETEROCYCLIC COMPOUNDS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; ORGANOMETALLIC COMPOUNDS; PEPTIDES; SUCCINIMIDES;

EID: 44649149708     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2007.11.002     Document Type: Article

References (31)

1. Tóth É., Helm L., and Merbach A.E. The chemistry of contrast agents in medical magnetic resonance imaging. In: Merbach A.E., and Tóth É. (Eds). Relaxivity of gadolinium(III) complexes: theory and mechanism (2001), John Wiley & Sons, Chichester 45-119
2. Caravan P., Ellison J.J., McMurry T.J., and Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99 (1999) 2293-2352
3. Aime S., Botta M., Fasano M., and Terreno E. Prototropic and water-exchange processes in aqueous solutions of Gd(III) chelates. Acc Chem Res 32 (1999) 941-949
4. 3-targeted magnetic resonance imaging. Nat Med 4 (1998) 623-626
5. Tiefenauer L.X., Kühne G., and Andres R.Y. Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjugate Chem 4 (1993) 347-352
6. Marecos E., Weissleder R., and Bogdanov Jr. A. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjugate Chem 9 (1998) 184-191
7. 3in cell lines and MR imaging with antibody-coated iron oxide particles. Magn Reson Med 56 (2006) 711-716
8. Huh Y.M., Jun Y., Song H.T., Kim S., Choi J., Lee J.H., et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 127 (2005) 12387-12391
9. Weinmann H.J., Ebert W., Misselwitz B., and Schmitt-Willich H. Tissue-specific MR contrast agents. Eur J Radiol 46 (2003) 33-44
10. Shahbazi-Gahrouei D., Williams M., Rizvi S., and Allen B.J. In vivo studies of Gd-DTPA-monoclonal antibody and Gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma. Magn Reson Imaging 14 (2001) 169-174
11. Konda S.D., Aref M., Brechbiel M., and Wiener E.C. Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress. Invest Radiol 35 (2000) 50-57
12. Montet X., Weissleder R., and Josephson L. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjugate Chem 17 (2006) 905-911
13. Högemann D., Josephson L., Weissleder R., and Basilion J.P. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjugate Chem 11 (2000) 941-946
14. Anelli P.L., Bertini I., Fragai M., Lattuada L., Luchinat C., and Parigi G. Sulfonamide-functionalized gadolinium DTPA complexes as possible contrast agents for MRI: a relaxometric investigation. Eur J Inorg Chem (2000) 625-630
15. Wolf M., Hull W.E., Mier W., Heiland S., Bauder-Wüst U., Kinscherf R., et al. Polyamine-substituted gadolinium chelates: a new class of intracellular contrast agents for magnetic resonance imaging of tumors. J Med Chem 50 (2007) 139-148
16. Leuschner C., Kumar C.S.S.R., Hansel W., Soboyejo W., Zhou J., and Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 99 (2006) 163-176
17. Lee J.H., Huh Y.M., Jun Y., Seo J., Jang J., Song H.T., et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 13 (2007) 95-99
18. De León-Rodríguez L.M., Ortiz A., Weiner A.L., Zhang S., Kovacs Z., Kodadek T., et al. Magnetic resonance imaging detects a specific peptide-protein binding event. J Am Chem Soc 124 (2002) 3514-3515
19. De León-Rodríguez L.M., Kovacs Z., Dieckmann G.R., and Sherry A.D. Solid-phase synthesis of DOTA-peptides. Chem Eur J 10 (2004) 1149-1155
20. Eldredge H.B., Spiller M., Chasse J.M., Greenwood M.T., and Caravan P. Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325. Invest Radiol 41 (2006) 229-243
21. Zhang Z., Greenfield M.T., Spiller M., McMurry T.J., Lauffer R.B., and Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Ed 44 (2005) 6766-6769
22. Aime S., Barge A., Cabella C., Geninatti Critch S., and Gianolio E. Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates. Curr Pharmaceut Biotech 5 (2004) 509-518
23. Morawski A.M., Winter P.M., Crowder K.C., Caruthers S.D., Fuhrhop R.W., Scott M.J., et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Mag Res Med (2004) 480-486
24. Hardcastle K.I., Botta M., Fasano M., and Digilio G. Experimental evidence for a second coordination sphere water molecule in the hydration structure of YbDTPA - insights for a re-assessment of the relaxivity data of GdDTPA. Eur J Inorg Chem (2000) 971-977
25. Louie A.Y., Hüber M.M., Ahrens E.T., Rothbächer U., Moats R., Jacobs R.E., et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 18 (2000) 321-325
26. Bennun L., Greaves E.D., and Blostein J.J. New procedure for intensity and detection limit determination in spectral trace analysis: application for trace mercury by TXRF. X-ray Spectrom 31 (2002) 289-295
27. Liang S.C., Wang H., Zhang Z.M., Zhang X., and Zhang H.S. Spectrofluorimetric determination of cysteine by 5-maleimidyl-2-(m-methylphenyl)benzoxazole. Spectrochim Acta Part A 58 (2002) 2605-2611
28. Yonezawa M., Doi N., Kawahashi Y., Higashinakagawa T., and Yanagawa H. DNA display for in vitro selection of diverse peptide libraries. Nucleic Acids Res 31 (2003) e118
29. 3+ complexes of interest in magnetic resonance imaging: an integrated and theoretically self-consistent approach. J Am Chem Soc 118 (1996) 9333-9346
30. 1 agents. Proc Natl Acad Sci U S A 95 (1998) 8443-8448
31. Backer M., Gaynutdinov T., Patel V., Bandyopadhyaya A., Thirumamagal B., Tjarks W., et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 4 (2005) 1423-1429